LeafLife · Ferramenta educativa

Sistema Endocanabinoide

Entenda, de forma visual, como receptores, canabinoides e produtos se conectam no corpo humano — com base em literatura científica. Selecione um item ao lado para ver as conexões refletidas no corpo e no cérebro.

Receptores

Canabinoides

Produtos

Legenda — relações
✅ ativa totalmente
◐ ativa parcialmente
🚫 bloqueia
⚡ influencia indiretamente
🚫/◐ efeito duplo (depende da dose)
Corpo
Cérebro (corte sagital, esquemático)
Ossos do crânio Meninges Córtex cerebral Corpo caloso Tálamo Hipotálamo Hipófise Epífise Mesencéfalo Ponte Bulbo Medula espinhal Cerebelo
Selecione um receptor, canabinoide ou produto para começar.
Referências (literatura científica)
  1. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30(10):515-527.
  2. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059-1068.
  3. Iversen L. Cannabis and the brain. Brain. 2003;126(6):1252-1270.
  4. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš LO. Cannabidiol — recent advances. Chem Biodivers. 2007;4(8):1678-1692.
  5. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-1349.
  6. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092-1101.
  7. Whyte LS, Ryberg E, Sims NA, et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA. 2009;106(38):16511-16516.
  8. Gantz I, Muraoka A, Yang YK, et al. Cloning and chromosomal localization of a gene (GPR18) encoding a novel seven transmembrane receptor highly expressed in spleen and testis. Genomics. 1997;42(3):462-466.
  9. McHugh D, Hu SS, Rimmerman N, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010;11:44.
  10. McHugh D, Page J, Dunn E, Bradshaw HB. Δ9-THC and N-arachidonyl glycine are full agonists at GPR18 and cause migration in the human endometrial cell line, HEC-1B. Br J Pharmacol. 2012;165(8):2414-2424.
  11. Zeng W, Wang Y, Gao R, Wen H, Yu M. Unlocking the reverse targeting mechanisms of cannabidiol: unveiling new therapeutic avenues. J Med Chem. 2024;67(16):14574-14585.
  12. Yang S, Du Y, Li Y, Tang Q, Zhang Y, Zhao X. Tyrosine phosphorylation and palmitoylation of TRPV2 ion channel tune microglial beta-amyloid peptide phagocytosis. J Neuroinflammation. 2024;21(1):218.
  13. Miao Y, Zhao F, Guan W. A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors. Int J Neuropsychopharmacol. 2025;28(2):pyae064.
  14. Tsien RW, Rosenberg EC. Ion channels and G protein-coupled receptors: cannabidiol actions on disorders of excitability and synaptic excitatory-inhibitory ratio. Mol Pharmacol. 2025;107(3):100017.
  15. Chan A, Silván CV. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegener Dis Manag. 2022;12(3):141-154.
  16. Hsu M, Shah A, Jordan A, Gold MS, Hill KP. Therapeutic Use of Cannabis and Cannabinoids: A Review. JAMA. 2026;335(4):345-359.
  17. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473.
  18. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226.
  19. Manduca A, Buzzelli V, Rava A, et al. Cannabidiol and positive effects on object recognition memory in an in vivo model of Fragile X Syndrome: Obligatory role of hippocampal GPR55 receptors. Pharmacol Res. 2024;203:107176.
  20. ALSalamat HA, Abuarab SF, Salamah HM, et al. Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer. J Cannabis Res. 2024;6(1):24.
  21. Aso E, Ferrer I. CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Front Neurosci. 2016;10:243.
  22. Navarrete F, García-Gutiérrez MS, Aracil-Fernández A, Lanciego JL, Manzanares J. Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease. Neurotherapeutics. 2018;15(2):459-469.
  23. Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021;12(1):6.
  24. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-165.
  25. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019;176(11):911-922.
  26. Wilson J, Dobson O, Langcake A, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026;13(4):304-315.
Todos os 8 receptores têm pelo menos um canabinoide do catálogo agindo sobre eles, com base em literatura científica (não no material de marketing/treinamento da LeafLife). O GPR119 não é apresentado aqui: é um receptor real do "endocanabinoidoma", mas nenhuma fonte encontrada mostra um fitocanabinoide (THC, CBD, CBG, CBN, CBC ou THCV) agindo diretamente nele — só ligantes produzidos pelo próprio corpo (oleoiletanolamida, 2-oleoilglicerol), confirmado em varredura de julho de 2026 restrita a publicações de 2024 em diante. Mapeamento receptor↔corpo/cérebro é uma simplificação didática desta ferramenta — as posições exatas de órgãos e estruturas cerebrais são esquemáticas, não anatomicamente precisas. Quando várias seleções ativam a mesma região, apenas uma cor é mostrada (limitação da ferramenta).